PRECLINICAL EVALUATION OF GROUP-B NEISSERIA-MENINGITIDIS AND ESCHERICHIA-COLI K92 CAPSULAR POLYSACCHARIDE-PROTEIN CONJUGATE VACCINES IN JUVENILE RHESUS-MONKEYS
Sjn. Devi et al., PRECLINICAL EVALUATION OF GROUP-B NEISSERIA-MENINGITIDIS AND ESCHERICHIA-COLI K92 CAPSULAR POLYSACCHARIDE-PROTEIN CONJUGATE VACCINES IN JUVENILE RHESUS-MONKEYS, Infection and immunity, 65(3), 1997, pp. 1045-1052
We reported the first use of group B meningococcal conjugate vaccines
in a nonhuman primate model (S. J. N. Devi, C. E. Frasch, W. Zollinger
, and P. J. Snoy, p. 427-429, in J. S. Evans, S. E. Yost, M. C. J. Mai
den, and I. M. Feavers, ed., Proceedings of the Ninth International Pa
thogenic Neisseria Conference, 1994), Three different group B Neisseri
a meningitidis capsular polysaccharide (B PS)-protein conjugate vaccin
es and an Escherichia coli K92 capsular polysaccharide-tetanus toroid
(K92-TT) conjugate vaccine are here evaluated for safety and relative
immunogenicities in juvenile rhesus monkeys with or without adjuvants,
Monkeys were immunized intramuscularly with either B PS-cross-reactiv
e material 197 conjugate, B PS-outer membrane vesicle (B-OMV) conjugat
e, or N-propionylated B PS-outer membrane protein 3 (N-pr. B-OMP3) con
jugate vaccine with or without adjuvants at weeks 0, 6, and 14. A cont
rol group of monkeys received one injection of the purified B PS alone
, and another group received three injections of B PS noncovalently co
mplexed,vith OMV. Antibody responses as measured by enzyme-linked immu
nosorbent assay varied among individual monkeys, All vaccines except B
PS and the K92-TT conjugate elicited a twofold or greater increase in
total B PS antibodies after one immunization, All vaccines, including
the K92-TT conjugate, elicited a rise in geometric mean B PS antibody
levels of ninefold or more over the preimmune levels following the th
ird immunization. Antibodies elicited by N-pr. B-OMP3 and B-OMV conjug
ates were directed to the N-propionylated or to the spacer-containing
B PS antigens as well as to the native B PS complexed with methylated
human serum albumin, None of the vaccines caused discernible safety-re
lated symptoms.